Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
|Videos|March 23, 2016
Susan Melvin Hill Tells Her MPN Story and Discusses Patient Advocacy
Author(s)Susan Melvin Hill
Susan Melvin Hill, patient advocate, tells her MPN story and discusses how she helps patients with myeloproliferative neoplasms (MPNs) in Idaho.
Advertisement
Susan Melvin Hill, patient advocate, tells her MPN story and discusses how she helps patients with myeloproliferative neoplasms (MPNs) in Idaho. Hill was named one of our
Advertisement
Related to this article
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.